Merck has stopped manufacturing and marketing Recarbrio, an antibiotic that targeted multidrug-resistant infections.  The FDA approved Recarbrio (cilastatin sodium, imipenem and relebactam) in July 2019 for adults with complicated urinary tract infections or complicated intra-abdominal infections who have limited or…

The FDA has approved Camzyos (mavacamten) capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Camzyos is now approved for adults and pediatric patients weighing at least 30 kilograms (approximately 66…

CMS has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory payment model that will tie Medicare Part B drug rebates to prices paid in 19 reference countries, according to a Sept. 30 CMS news release. Here…

The 100% Section 232 tariff on patented pharmaceuticals and associated pharmaceutical ingredients took full effect Sept. 29 for companies not already covered under the July 31 implementation date. The Commerce Department’s Bureau of Industry and Security has defined which specialty…

The Pharmaceutical Research and Manufacturers of America has named Eric Cantor its next president and CEO, effective Nov. 9. Mr. Cantor will succeed Stephen Ubl, who has led PhRMA since 2015, according to a Sept. 29 news release. Mr. Ubl…

California has removed prior authorization requirements for medically necessary direct-acting antiviral drugs used to treat hepatitis C. Gov. Gavin Newsom signed the legislation Sept. 27. It bars health care service plans and health insurers from subjecting medically necessary direct-acting antiviral…

Health systems are facing a hard question: as site-of-care pressure pushes more infusion volume away from the hospital outpatient department (HOPD), how do they keep appropriate care inside the system? The infusion market keeps growing — spending is projected to…

A September 2026 American Medical Association Policy Research Perspective analyzed Decision Resources Group data on PBM and insurer market shares from 2022 to 2024. Together, the four largest PBMs controlled 75% of the national market, up from 70% in 2022.…

It’s the end of the world as we know it; panic and mass hysteria. That is roughly the tone of recent coverage of the pharmacy changes arriving in 2027, and it is worth turning the volume down, because the truth…

The FDA has approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. Emcitate is the first FDA-approved treatment for peripheral thyrotoxicosis in patients with the rare genetic disorder, according to a Sept.…